医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Limited to Present at the Jefferies 2018 Healthcare Conference

2018年06月05日 PM10:10
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2018 Healthcare Conference on Wednesday, June 6th, 2018, in New York City.

The presentation is scheduled to begin at 3:00 p.m. EDT [12:30 a.m. IST on June 7th, 2017].

Presentation material will be available on the Company’s website www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180605006032/en/

CONTACT

DR. REDDY’S LABORATORIES LTD.
INVESTOR RELATIONS
SAUNAK
SAVLA
saunaks@drreddys.com
Ph:
+91-40-49002135
or
MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
Ph:
+91-40- 49002121

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
  • 内布拉斯加大学医学中心和阿南达宣布,FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验
  • Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
  • Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods
  • MSITEK Sponsors a Hospice IT and Digital Project in India as Part of CSR (Corporate Social Responsibility) Initiatives